Combination therapy with ampicillin and azithromycin improved outcomes in a mouse model of group B streptococcal sepsis

PLoS ONE

Volumn 12, Issue 7, 2017, Pages

  Upadhyay, Kirtikumar ^a,b   Hiregoudar, Basu ^c   Meals, Elizabeth ^a,b   English, Boyce Keith ^d   Talati, Ajay J ^a,b  

^a LE BONHEUR CHILDREN'S MEDICAL CENTER   (United States)

^b UNIVERSITY OF TENNESSEE HEALTH SCIENCE CENTER   (United States)

^c Cheyenne Regional Medical Center   (United States)

^d MICHIGAN STATE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMPICILLIN; AZITHROMYCIN; INTERLEUKIN 10; INTERLEUKIN 6; MACROPHAGE INFLAMMATORY PROTEIN 1ALPHA; TUMOR NECROSIS FACTOR; ANTIINFECTIVE AGENT; CYTOKINE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIBIOTIC RESISTANCE; ARTICLE; BACTERIUM ISOLATION; CONCENTRATION RESPONSE; CONTROLLED STUDY; CYTOKINE PRODUCTION; CYTOKINE RELEASE; FEMALE; GROUP B STREPTOCOCCAL INFECTION; HUMAN; IN VITRO STUDY; IN VIVO STUDY; MONOTHERAPY; MOUSE; NONHUMAN; PROTEIN BLOOD LEVEL; TREATMENT OUTCOME; ANIMAL; BLOOD; CELL LINE; COMBINATION DRUG THERAPY; SEPSIS; STREPTOCOCCAL INFECTIONS;

AMPICILLIN; ANIMALS; ANTI-BACTERIAL AGENTS; AZITHROMYCIN; CELL LINE; CYTOKINES; DRUG THERAPY, COMBINATION; FEMALE; MICE; SEPSIS; STREPTOCOCCAL INFECTIONS;

EID: 85026432125     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0182023     Document Type: Article

References (40)

1. Krohn M. A., L Hillier S., and Baker C. J. Maternal peripartum complications associated with vaginal group B streptococci colonization. J. Infect. Dis.1999; 179:1410–1415. https://doi.org/10.1086/314756PMID: 10228062
2. Schrag S. J., Zywicki S., Farley M. M., Reingold AL, Harrison LH, Lefkowitz LB et al. Group B streptococcal disease in the era of intrapartum antibiotic prophylaxis.N. Engl. J. Med.2000; 342:15–20. https://doi.org/10.1056/NEJM200001063420103 PMID: 10620644
3. Velaphi S, Siegel JD, Wendel GD Jr, Cushion N, Eid WM, Sánchez PJ. Early onset group B streptococcal infection after a combined maternal and neonatal group B streptococcal chemoprophylaxis strategy. Pediatrics 2003; 111:541–547. PMID: 12612234
4. Libster R, Edwards K, Levent F, Edwards MS, Rench MA, Castagnini LA et al. Long-term Outcomes of Group B Streptococcal Meningitis. Pediatrics 2012; 130(1):e8–15. https://doi.org/10.1542/peds.2011-3453 PMID: 22689869
5. Austrian R, Gold J. Pneumococcal bacteremia with especial reference to bacteremic pneumococcal pneumonia. Ann Intern Med 1964; 60:759–76. PMID: 14156606
6. Mandell LA, Wunderink RG, Anzueto A, Bartlett J, Campbell G, Dean N et al. Infectious Diseases Society of America/American Thoracic Society consensus guidelines on the management of community-acquired pneumonia in adults. Clin Infect Dis 2007; 44(Suppl 2):S27–72.
7. Kohanski MA, Dwyer DJ, Collins JJ. How antibiotics kill bacteria: from targets to networks. Nature reviews Microbiology. 2010; 8(6):423–435. https://doi.org/10.1038/nrmicro2333 PMID: 20440275
8. Mancuso G, Midiri A, Beninati C, Biondo C, Galbo R, Akira S et al. Dual role of TLR2 and myeloid differentiation factor 88 in a mouse model of invasive group B streptococcal disease. J Immunol 2004; 172 (10):6324–6329. PMID: 15128822
9. Cusumano V, Genovese F, Mancuso G, Carbone M, Fera M T, and Teti G. Interleukin-10 protects neonatal mice from lethal group B streptococcal infection. Infect Immun 1996; 64(7):2850–2852. PMID: 8698523
10. Mancuso G, Cusumano V, Cook JA, Smith E, Squadrito F, Blandino G et al. Efficacy of tumor necrosis factor alpha and eicosanoid inhibitors in experimental models of neonatal sepsis. FEMS Immunol Med Microbiol 1994; 9(1):49–54. PMID: 7920463
11. Mancuso G, Tomasello F, Migliardo M, Delfino D, Cochrane J, Cook JA et al. Beneficial effects of interleukin-6 in neonatal mouse models of group B streptococcal disease. Infect Immun 1994; 62 (11):4997–5002. PMID: 7927780
12. Marriott HM, Mitchellm TJ, and Dockrell DH. Pneumolysin: a double-edged sword during the host-pathogen interaction. Current Molecular Medicine 2008; 8: 497–509. PMID: 18781957
13. Spreer A, Kerstan H, Böttcher T, Gerber J, Seimer A, Zysk G et al. Reduced release of pneumolysin by Streptococcus pneumoniae in vitro and in vivo after treatment with nonbacteriolytic antibiotics in comparison to ceftriaxone. Antimicrobial Agents and Chemotherapy 2003; 47: 2649–2654. https://doi.org/10.1128/AAC.47.8.2649-2654.2003 PMID: 12878534
14. Karlstrom A, Boyd KL, English BK, McCullers JA. Treatment with protein synthesis inhibitors improves outcomes of secondary bacterial pneumonia after influenza. J Infect Dis 2009; 199: 1–9. https://doi.org/10.1086/595568
15. Mufson MA, Stanek RJ. Bacteremic pneumococcal pneumonia in one American City: a 20-year longitudinal study, 1978–1997. Am J Med. 1999; 107:34S–43S.
16. Waterer GW, Somes GW, Wunderink RG. Monotherapy may be suboptimal for severe bacteremic pneumococcal pneumonia. Arch Intern Med. 2001; 161:1837–1842. PMID: 11493124
17. Martinez JA, Horcajada JP, Almela M, Marco F, Soariano A, Garcia E et al. Addition of a macrolide to a beta-lactam-based empirical antibiotic regimen is associated with lower in-hospital mortality for patients with bacteremic pneumococcal pneumonia. Clin Infect Dis. 2003; 36:389–395. https://doi.org/10.1086/367541 PMID: 12567294
18. Baddour LM, Yu VL, Klugman KP, Feldman C, Ortgvist A, Rello J et al. Combination antibiotic therapy lowers mortality among severely ill patients with pneumococcal bacteremia. Am J Respir Crit Care Med. 2004; 170:440–444. https://doi.org/10.1164/rccm.200311-1578OC PMID: 15184200
19. Zuckerman JM, Qamar F, and Bono BR. Review of macrolides (azithromycin, clarithromycin), ketolides (telithromycin) and glycylcyclines (tigecycline). Medical Clinics of North America 2011; 95:761–791. https://doi.org/10.1016/j.mcna.2011.03.012 PMID: 21679791
20. Foulds G, Shepard RM, and Johnson RB. The pharmacokinetics of azithromycin in human serum and tissues. Journal of Antimicrobial Chemotherapy 1990; 25:73–82.
21. Brinkmann KC, Talati AJ, Akbari RE, English BK. Group B streptococci exposed to rifampin or clindamy-cin (versus ampicillin or cefotaxime) stimulate reduced production of inflammatory mediators by murine macrophages. Pediatr Res. 2005; 57(3):419–23. https://doi.org/10.1203/01.PDR.0000153946.97159. 79 PMID: 15635047
22. Jiang JH, Chiu NC, Huang FY, Kao HA, Hsu CH, Hung HY et al. Neonatal sepsis in the neonatal intensive care unit: characteristics of early versus late onset; J Microbiol Immunol Infect 2004; 37:301–306 PMID: 15497012
23. Klein JO. Bacterial sepsis and meningitis. In: Remington JS, Klein JO, eds. Infectious disease of the fetus and newborn infant. 5th ed. Philadelphia: W.B. Saunders; 2001:943–98.
24. Edmond KM, Kortsalioudaki C, Scott S, Schrag SJ, Zaidi AKM, Cousens S et al. Group B streptococcal disease in infants aged younger than 3 months: systematic review and meta-analysis. Lancet. 2012; 379:547–56 https://doi.org/10.1016/S0140-6736(11)61651-6 PMID: 22226047
25. Phares CR, Lynfield R, Farley MM, Mohle-Boetani J, Harrison H, Petit S et al. Epidemiology of invasive group B streptococcal disease in the United States, 1999–2005. JAMA 2008; 299:2056–65. https://doi.org/10.1001/jama.299.17.2056 PMID: 18460666
26. Orman KL, English BK. Effects of antibiotic class on the macrophage inflammatory response to Streptococcus pneumoniae. J Infect Dis. 2000; 182(5):1561–1565 https://doi.org/10.1086/315861 PMID: 11023483
27. Odio CM, Faingezicht I, Paris M, Nassar M, Baltodano A, Rogers J et al. The beneficial effects of early dexamethasone administration in infants and children with bacterial meningitis. N Engl J Med. 1991; 324(22):1525–1531. https://doi.org/10.1056/NEJM199105303242201 PMID: 2027357
28. Quagliarello V, Scheld WM. Bacterial meningitis: pathogenesis, pathophysiology, and progress. N Engl J Med. 1992; 327(12):864–872. https://doi.org/10.1056/NEJM199209173271208 PMID: 1508247
29. Smith MW, Schmidt JE, Rehg JE, Orihuela CJ, McCullers JA. Induction of pro- and anti- inflammatory molecules in a mouse model of pneumococcal pneumonia following influenza. Comp Med 2007; 57 (1):82–9. PMID: 17348295
30. Feldman WE. Concentrations of bacteria in cerebrospinal fluid of patients with bacterial meningitis. J Pediatr 1976; 88:549–552 PMID: 3635
31. Nau R, Wellmer A, Soto A, Koch K, Schneider O, Schmidt H et al. Rifampin reduces early mortality in experimental Streptococcus pneumoniae meningitis. J Infect Dis. 1999; 179(6):1557–1560. https://doi.org/10.1086/314760 PMID: 10228082
32. Sligl W, Hoang H, Eurich D, Malhotra A, Marrie TJ, Majumdar SR. Macrolide use in the treatment of critically ill patients with pneumonia: Incidence, correlates, timing and outcomes. Can J Infect Dis Med Microbiol 2013; 24(4):e107–112. PMID: 24489569
33. Giamarellos-Bourboulis E, Mylona V, Antonopoulou A, Tsangaris I, Koutelidakis I, Marioli A et al. Effect of clarithromycin in patients with suspected Gram-negative sepsis: results of a randomized controlled trial. J Antimicrob Chemother 2014; 69: 1111–1118. https://doi.org/10.1093/jac/dkt475 PMID: 24292991
34. Walkey A, Weiner R. Macrolide antibiotics and survival in patients with acute lung injury. CHEST 2012; 141(5):1153–1159. https://doi.org/10.1378/chest.11-1908 PMID: 22116799
35. Crosbie PA, Woodhead MA. Long-term macrolide therapy in chronic inflammatory airway diseases. Eur Respir J 2009; 33:171–181. https://doi.org/10.1183/09031936.00042208 PMID: 19118228
36. Murphy DM, Forrest IA, Curran D, Ward C. Macrolide antibiotics and the airway: antibiotic or non-antibiotic effects? Expert Opin Investig Drugs 2010; 19:401–414. https://doi.org/10.1517/ 13543781003636480 PMID: 20151856
37. Hiwatashi Y, Maeda M, Fukushima H, Onda K, Tanaka S, Utsumi H et al. Azithromycin suppresses proliferation, interleukin production and mitogen-activated protein kinases in human peripheral-blood mononuclear cells stimulated with bacterial superantigen. J Pharm Pharmacol. 2011; 63(10):1320–6. https://doi.org/10.1111/j.2042-7158.2011.01343.x PMID: 21899548
38. Corannachione P, Scaringi L, Fettucciari K, Rosati E, Sabatini R, Orefici G et al. Group B streptococci persist inside macrophages. Immunology. 1998; 93(1):86–95. PMID: 9536123
39. Talati AJ, Crouse D, English BK, Newman C, Harrison L, Meals E. Immunomodulation by Exogenous surfactant: Effect on TNF-α secretion and luminol- Enhanced Chemi Luminescence Activity by murine macrophages stimulated with group B streptococci. Microbes and Infection 2001; 3:267–273. PMID: 11334743
40. Ullman-Culleré MH and Foltz CJ. Body Condition Scoring: A Rapid and Accurate Method for Assessing Health Status in Mice; Laboratory Animal Science 1999; 49:3.